Currently, there are no effective treatments available to address the progression of inherited retinal disorders such as RP, except for RPE65 gene therapy (voretigene neparvovecrzyl, Luxturna; Spark Therapeutics). The gene discussed is RPE65; the disease is retinitis pigmentosa 1.